Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections
Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections
复制标题
DOI：
10.1007/s10534-014-9743-6
复制
发表时间：
2014-08-01
期刊：
影响因子：
3.5
通讯作者：
Messori, Luigi
中科院分区：
文献类型：
--
作者：
Cassetta, Maria Iris;Marzo, Tiziano;Messori, Luigi
金诺芬(Auranofin，AF)是一种临床上用于治疗类风湿关节炎的金(I)络合物，在体外对葡萄球菌有显著的杀菌作用。值得注意的是，对少数耐甲氧西林的金黄色葡萄球菌菌株也有类似的抗菌作用和效力，但对大肠杆菌没有。通过记录时间杀灭曲线，表征了AF抗菌作用的时间和浓度依赖关系，并突出了浓度依赖曲线。总体而言，目前的结果指出，金诺芬可能会迅速和成功地用于治疗由耐药葡萄球菌引起的严重细菌感染。
Auranofin, (AF), a gold(I) complex in clinical use for the therapy of rheumatoid arthritis, is reported here to produce remarkable bactericidal effects in vitro against Staphylococcus sp. Noticeably, a similar antimicrobial action and potency are also noticed toward a few methicillin-resistant Staphylococcus aureus strains but not toward Escherichia coli. The time and concentration dependencies of the antimicrobial actions of AF have been characterized through recording time kill curves, and a concentration dependent profile highlighted. Overall, the present results point out that auranofin might be quickly and successfully repurposed for the treatment of severe bacterial infections due to resistant Staphylococci.